down arrow

Atara Biotherapeutics, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US0465131078
USD
14.20
1.98 (16.2%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Comparison
Company
Score
Quality
Valuation
Financial
Technical
Zevra Therapeutics, Inc.
XOMA Corp.
Emergent BioSolutions, Inc.
Verrica Pharmaceuticals, Inc.
Alimera Sciences, Inc.
Applied Therapeutics, Inc.
Zomedica Corp.
Fusion Pharmaceuticals, Inc.
Atara Biotherapeutics, Inc.
Sagimet Biosciences, Inc.
Tenaya Therapeutics, Inc.
Why is Atara Biotherapeutics, Inc. ?
1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 15.59% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -182.29
2
Risky - Negative Operating Profits
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 20.21%, its profits have risen by 97.5%
stock-recommendationReal-Time Research Report
Verdict Report
How much should you sell?
  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Atara Biotherapeutics, Inc. for you?

High Risk, Medium Return

Absolute
Risk Adjusted
Volatility
Atara Biotherapeutics, Inc.
11.64%
0.12
99.20%
S&P 500
13.22%
0.61
20.17%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors
Factor
Value
Sales Growth (5y)
185.50%
EBIT Growth (5y)
15.59%
EBIT to Interest (avg)
-182.29
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.72
Sales to Capital Employed (avg)
-13.84
Tax Ratio
0.23%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
85.97%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation
Valuation Scorecard stock-summary
stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
-1.14
EV to EBIT
-31.84
EV to EBITDA
62.71
EV to Capital Employed
-6.71
EV to Sales
0.51
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals
Technical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
No Trend
Mildly Bullish
OBV
No Trend
Mildly Bullish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
Analyse All Technical Factors stock-recommendation
stock-recommendationFinancial Trend
Financial Trend Scorecard stock-summary
stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

27What is working for the Company
OPERATING CASH FLOW(Y)

Highest at USD -63.92 MM

NET SALES(HY)

At USD 115.72 MM has Grown at 106.66%

PRE-TAX PROFIT(Q)

At USD 3.91 MM has Grown at 120.93%

NET PROFIT(Q)

At USD 3.91 MM has Grown at 120.91%

RAW MATERIAL COST(Y)

Fallen by -15.7% (YoY

DEBTORS TURNOVER RATIO(HY)

Highest at 149.62 times

-5What is not working for the Company
CASH AND EQV(HY)

Lowest at USD 36.31 MM

NET SALES(Q)

Lowest at USD 17.57 MM

Here's what is working for Atara Biotherapeutics, Inc.
Operating Cash Flow
Highest at USD -63.92 MM and Grown
In each year in the last three years
MOJO Watch
The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Pre-Tax Profit
At USD 3.91 MM has Grown at 120.93%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is very positive

Pre-Tax Profit (USD MM)

Net Profit
At USD 3.91 MM has Grown at 120.91%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is very positive

Net Profit (USD MM)

Debtors Turnover Ratio
Highest at 149.62 times
in the last five Semi-Annual periods
MOJO Watch
Company has been able to sell its Debtors faster

Debtors Turnover Ratio

Raw Material Cost
Fallen by -15.7% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Atara Biotherapeutics, Inc.
Net Sales
At USD 17.57 MM has Fallen at -38.63%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Net Sales
Lowest at USD 17.57 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (USD MM)

Cash and Eqv
Lowest at USD 36.31 MM
in the last six Semi-Annual periods
MOJO Watch
Short Term liquidity is deteriorating

Cash and Cash Equivalents

Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."